Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260202 | 0.93 | PDGFRB (0.76) | PDGFRB | |
| SCHEMBL12260201 | 0.89 | PDGFRB (0.76) | PDGFRB | |
| SCHEMBL6711156 | 0.85 | PDGFRB (0.70) | PDGFRB | |
| SCHEMBL6713140 | 0.85 | PDGFRB (0.93) | PDGFRB | |
| SCHEMBL1132841 | 0.84 | PDGFRB (0.87) | PDGFRB | |
| SCHEMBL6710982 | 0.82 | PDGFRB (0.56) | PDGFRB | |
| SCHEMBL2916045 | 0.82 | PDGFRB (0.70) | PDGFRB | |
| SCHEMBL6709598 | 0.82 | PDGFRB (0.55) | PDGFRB | |
| SCHEMBL12861678 | 0.82 | PDGFRB (0.81) | PDGFRB | |
| SCHEMBL6709538 | 0.81 | PDGFRB (1.00) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7329655-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329655-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | WNK2, NPR1, NPR3 | PDGFRB 9/4885 |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | WNK2, CDK5, WNK1 | PDGFRB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.